NewLink Genetics: Annual Report 2014 (NewLink Genetics) - Mar 21, 2015 - Anticipated expiry of patents for pharmaceutical compositions for inhibiting pre-established tumor growth comprising attenuated allogeneic tumor cells modified with alpha-Gal and methods of manufacturing in US, EU, Mexico, Japan and Canada in 2024
Anticipated patent expiry • Non Small Cell Lung Cancer
|